Icon (NASDAQ:ICLR) Shares Gap Down – Here’s Why

Icon Plc (NASDAQ:ICLR)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $178.18, but opened at $165.75. Icon shares last traded at $163.7160, with a volume of 178,616 shares.

Key Headlines Impacting Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Truist reaffirmed its “Buy” rating and raised its price target to $209 from $207, implying substantial upside based on the referenced share price. The target increase signals continued confidence in Icon’s long-term growth prospects. Benzinga analyst rating report
• Positive Sentiment: Icon reported second-quarter revenue of approximately $2.06 billion, above the roughly $2.00 billion consensus estimate, with revenue growing 2.3% from the prior-year period. The earnings call also emphasized a strong surge in bookings, supporting future revenue visibility. Q2 2026 earnings call highlights
• Positive Sentiment: Zacks upgraded ICLR from “Strong Sell” to “Hold,” suggesting its view has improved even though the firm remains cautious. Zacks rating update
• Neutral Sentiment: Quarterly adjusted EPS was $2.56, narrowly above some consensus estimates of $2.55, although another Zacks estimate was $2.57. The mixed comparison makes the earnings beat less decisive for investors. Icon Q2 earnings snapshot
• Negative Sentiment: EPS fell sharply from $3.26 a year earlier, while the earnings call highlighted margin pressures. The weaker profitability, despite higher revenue and bookings, is likely the main factor tempering the bullish analyst commentary. ICON Q2 2026 earnings call transcript

Analysts Set New Price Targets

A number of research firms have issued reports on ICLR. UBS Group set a $160.00 price objective on shares of Icon in a report on Wednesday, June 24th. BMO Capital Markets raised their target price on shares of Icon from $160.00 to $187.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Royal Bank Of Canada upgraded shares of Icon from a “sector perform” rating to an “outperform” rating and lifted their price target for the company from $126.00 to $185.00 in a research report on Thursday, June 25th. Truist Financial reiterated a “buy” rating and issued a $209.00 price target (up from $207.00) on shares of Icon in a research note on Friday. Finally, Barclays increased their price target on Icon from $160.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Thursday, June 25th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $170.40.

Icon Price Performance

The company’s 50-day moving average is $156.70 and its two-hundred day moving average is $135.62. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.95 and a quick ratio of 1.14. The firm has a market cap of $12.52 billion, a P/E ratio of 38.40, a PEG ratio of 8.12 and a beta of 1.22.

Icon (NASDAQ:ICLR) last released its earnings results on Wednesday, July 29th. The medical research company reported $2.56 EPS for the quarter, beating the consensus estimate of $2.55 by $0.01. The firm had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the firm earned $3.26 EPS. Sell-side analysts anticipate that Icon Plc will post 9.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Toth Financial Advisory Corp bought a new position in shares of Icon in the 4th quarter valued at $27,000. EFG International AG bought a new stake in shares of Icon during the 4th quarter worth $27,000. Abound Financial LLC bought a new stake in shares of Icon during the 4th quarter worth $54,000. GAMMA Investing LLC boosted its stake in Icon by 21.4% in the second quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock valued at $68,000 after buying an additional 69 shares in the last quarter. Finally, Johnson Financial Group Inc. acquired a new stake in Icon in the third quarter valued at about $71,000. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.